Literature DB >> 12496841

Pathologic progression of autochthonous prostate cancer in the TRAMP model.

J R Gingrich1, R J Barrios, B A Foster, N M Greenberg.   

Abstract

The ability to manipulate gene expression in specific cell types at specific times utilizing transgenic technology has allowed the development of novel mouse model systems that can mimic human disease. We have previously established the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model for prostate cancer using the rat probasin promoter to direct expression of the SV40 early genes to prostate epithelium. Male TRAMP mice exhibit consistent prostate-specific patterns of expression and develop prostatic intraepithelial neoplasia that will become invasive and metastasize primarily to the lymph nodes and lungs. In this paper we report our continued experience with this model and present a standardized histologic grading system to designate low and high grade prostatic intraepithelial neoplasia and well, moderate, and poorly differentiated prostate adenocarcinoma. In addition, we demonstrate the persistence of androgen receptor expression during pathologic progression and characterize heterogeneous cytokeratin expression in localized and metastatic prostate cancer. Finally, we report on our observations that phenotypic variability in tumor and pathologic progression in TRAMP occurs as a function of genetic background.

Entities:  

Year:  1999        PMID: 12496841     DOI: 10.1038/sj.pcan.4500296

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  91 in total

1.  Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Authors:  Marianne A Mihalyo; Adam T Hagymasi; Aaron M Slaiby; Erin E Nevius; Adam J Adler
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

2.  Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.

Authors:  Rana P Singh; Komal Raina; Girish Sharma; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.

Authors:  Jody T Mack; Kristi L Helke; Gabrielle Normand; CoDanielle Green; Danyelle M Townsend; Kenneth D Tew
Journal:  Cancer Lett       Date:  2010-10-30       Impact factor: 8.679

4.  Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer.

Authors:  Merrill J Christensen; Trevor E Quiner; Heather L Nakken; Edwin D Lephart; Dennis L Eggett; Paul M Urie
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

5.  Prostatic intraepithelial neoplasia in genetically engineered mice.

Authors:  Jae-Hak Park; Judy E Walls; Jose J Galvez; Minjung Kim; Cory Abate-Shen; Michael M Shen; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

7.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Authors:  Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

8.  False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models.

Authors:  M D Lawrence; B J Blyth; R J Ormsby; W D Tilley; P J Sykes
Journal:  Transgenic Res       Date:  2013-02-20       Impact factor: 2.788

9.  Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate.

Authors:  M Veronica Clavijo Jordan; Su-Tang Lo; Shiuhwei Chen; Christian Preihs; Sara Chirayil; Shanrong Zhang; Payal Kapur; Wen-Hong Li; Luis M De Leon-Rodriguez; Angelo J M Lubag; Neil M Rofsky; A Dean Sherry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

10.  Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.

Authors:  Cory K Mavis; Shannon R Morey Kinney; Barbara A Foster; Adam R Karpf
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.